3MeO-2oxo-PCP

The following information was compiled in April 2026 and is subject to change as new research is conducted and as new information becomes available:

Description: 3MeO-2oxo-PCP is a novel synthetic hallucinogen classified as an arylcyclohexylamine bearing structural resemblance to other phencyclidine (PCP) analogues (e.g., 3,4-methylenedioxy-PCP, 2oxo-PCP, 3MeO-PCP). No information is currently available on the pharmacology of 3MeO-2oxo-PCP; however, based on structural similarities to other arylcyclohexylamine analogues, it is hypothesized that 3MeO-2oxo-PCP acts as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor and can cause various effects including tachycardia, hypertension, confusion, agitation, and hallucinations.^1-4 3MeO-2oxo-PCP was first identified at the CFSRE in a postmortem peripheral blood specimen from California in March 2026 and was detected alongside mitragynine. 3MeO-2oxo-PCP has been identified in one drug material to date at the CFSRE. 3MeO-2oxo-PCP is not currently scheduled in the United States.

Class:

Hallucinogen

Appearance:

Blood

Formula:

C18H25NO2

MW:

287.4

[M+]:

287

[M+H]+:

288.1958

IUPAC:

2-(3-methoxyphenyl)-2-(piperidin-1-yl)cyclohexan-1-one

Report Date:

March 20, 2026